Shares of Vascular Solutions Inc. (NASDAQ:VASC) reached a new 52-week high on Monday . The stock traded as high as $44.27 and last traded at $43.77, with a volume of 48,172 shares trading hands. The stock had previously closed at $43.51.

Several research firms recently weighed in on VASC. Piper Jaffray Cos. restated an “overweight” rating and issued a $45.00 price objective (up from $44.00) on shares of Vascular Solutions in a report on Wednesday, April 27th. Zacks Investment Research upgraded shares of Vascular Solutions from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a report on Thursday, April 28th.

The stock has a market capitalization of $757.38 million and a price-to-earnings ratio of 95.40. The company has a 50-day moving average price of $39.71 and a 200 day moving average price of $33.53.

Vascular Solutions (NASDAQ:VASC) last issued its earnings results on Monday, April 25th. The medical device company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. During the same period last year, the business earned $0.21 earnings per share. The company earned $39 million during the quarter, compared to analyst estimates of $38.37 million. The firm’s revenue was up 13.9% compared to the same quarter last year. Analysts predict that Vascular Solutions Inc. will post $1.21 EPS for the current fiscal year.

In other news, Director Martin J. Emerson sold 20,000 shares of the stock in a transaction on Friday, May 13th. The stock was sold at an average price of $37.93, for a total transaction of $758,600.00. Following the completion of the transaction, the director now directly owns 8,435 shares in the company, valued at approximately $319,939.55. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Howard Root sold 34,418 shares of the stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $39.05, for a total value of $1,344,022.90. Following the transaction, the chief executive officer now owns 348,340 shares of the company’s stock, valued at $13,602,677. The disclosure for this sale can be found here.

Several institutional investors have added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its position in Vascular Solutions by 0.5% in the fourth quarter. Nationwide Fund Advisors now owns 31,649 shares of the medical device company’s stock worth $1,088,000 after buying an additional 153 shares in the last quarter. California State Teachers Retirement System boosted its position in Vascular Solutions by 1.3% in the fourth quarter. California State Teachers Retirement System now owns 31,944 shares of the medical device company’s stock worth $1,099,000 after buying an additional 414 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Vascular Solutions by 10.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 108,609 shares of the medical device company’s stock worth $3,735,000 after buying an additional 9,965 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Vascular Solutions by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 614,337 shares of the medical device company’s stock worth $21,128,000 after buying an additional 23,334 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.